Comparison of Spironolactone plus Cyproterone Acetate plus Cyproterone Compound with Spironolactone plus Cyproterone Compound in Hirsutism: A randomized clinical trial

Monotherapy is not usually effective in the treatment of hirsutism. Comparison of 2 therapeutic regimens in the treatment of hirsutism. Patients and In this open parallel controlled clinical trial، 101 Patients suffering from hirsutism were randomly divided into two equal groups. 50 patients were treated with spironolactone (50 mg/day) plus cyproterone compound (From 5th to 26th day of menstrual cycle) and the other group (51 patients) received cyproterone acetate 50 mg/day (From 5th to 14th day of menstrual cycle) in addition to the above mentioned drugs for 6 months. The serum level of sex hormones and hirsutism score (Ferriman-Gallway) were determined before and after treatment. T-test، chi-2 test and linear regression analysis were used for data analysis. Mean hirsutism score was 22. 12±0. 34 in first group and 22. 15±0. 34 in second group before treatment. Hirsutism score was reduced to 12. 74±0. 32 after treatment with 3 drugs and reduced to 16. 73±0. 35 after treatment with 2 drugs. This reduction was significantly more in the first group after adjustment for other confounding variables (P<0. 001). These two therapeutic regimens were both effective in the treatment of hirsutism without serious hepatic، renal and metabolic side effects. Treatment with 3 anti-androgen drugs was more effective in reduction of hirsutism scores.